Overactive Bladder Treatment market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach ...
An important question is how PTNS compares with the established alternatives for the treatment of overactive bladder. Established treatments would include non-pharmacologic measures such as ...
The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...
Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...
In his regular column, Dr James Le Fanu answers your questions. This week, a reader asks whether her overactive bladder ...
The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.
Peeing during sex is quite common among women. It may be due to sexual arousal or urinary tract infection. There are more ...
Gemtesa is approved for men with overactive bladder symptoms who are receiving pharmacologic treatment for benign prostatic hyperplasia.
Urinary incontinence, or leakage of urine, is a very common condition for women of all ages, ethnicities and backgrounds.